NZ535487A - Administration of ATIII by inhalation provides more efficient treatment of lung disorders such as lung inflammation and injury than intravenous administration - Google Patents
Administration of ATIII by inhalation provides more efficient treatment of lung disorders such as lung inflammation and injury than intravenous administrationInfo
- Publication number
- NZ535487A NZ535487A NZ535487A NZ53548703A NZ535487A NZ 535487 A NZ535487 A NZ 535487A NZ 535487 A NZ535487 A NZ 535487A NZ 53548703 A NZ53548703 A NZ 53548703A NZ 535487 A NZ535487 A NZ 535487A
- Authority
- NZ
- New Zealand
- Prior art keywords
- atiii
- antithrombin iii
- lung
- lung injury
- administration
- Prior art date
Links
- 108090000935 Antithrombin III Proteins 0.000 title claims abstract description 15
- 208000004852 Lung Injury Diseases 0.000 title claims description 16
- 206010035664 Pneumonia Diseases 0.000 title claims description 16
- 206010069363 Traumatic lung injury Diseases 0.000 title claims description 16
- 208000019693 Lung disease Diseases 0.000 title description 16
- 238000011282 treatment Methods 0.000 title description 11
- 230000006378 damage Effects 0.000 title description 10
- 238000001990 intravenous administration Methods 0.000 title description 4
- 102100022977 Antithrombin-III Human genes 0.000 title 1
- 102000004411 Antithrombin III Human genes 0.000 claims abstract description 14
- 229960005348 antithrombin iii Drugs 0.000 claims abstract description 14
- 206010069351 acute lung injury Diseases 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 9
- 230000037396 body weight Effects 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 231100000515 lung injury Toxicity 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 239000006199 nebulizer Substances 0.000 claims description 7
- 239000000779 smoke Substances 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 241000589516 Pseudomonas Species 0.000 claims description 4
- 239000010425 asbestos Substances 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 229910052895 riebeckite Inorganic materials 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000000443 aerosol Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 13
- 241001494479 Pecora Species 0.000 description 11
- 208000021063 Respiratory fume inhalation disease Diseases 0.000 description 11
- 206010040047 Sepsis Diseases 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000757319 Homo sapiens Antithrombin-III Proteins 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 101150034459 Parpbp gene Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36899702P | 2002-04-01 | 2002-04-01 | |
| PCT/US2003/009053 WO2003084476A2 (en) | 2002-04-01 | 2003-03-25 | Treatment of lung disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ535487A true NZ535487A (en) | 2008-12-24 |
Family
ID=29420316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ535487A NZ535487A (en) | 2002-04-01 | 2003-03-25 | Administration of ATIII by inhalation provides more efficient treatment of lung disorders such as lung inflammation and injury than intravenous administration |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090221475A9 (enExample) |
| EP (1) | EP1494696A4 (enExample) |
| JP (2) | JP2005527570A (enExample) |
| KR (2) | KR20040105838A (enExample) |
| CN (1) | CN100384469C (enExample) |
| AU (3) | AU2003233428B2 (enExample) |
| CA (1) | CA2480790A1 (enExample) |
| IL (2) | IL164078A0 (enExample) |
| NZ (1) | NZ535487A (enExample) |
| WO (1) | WO2003084476A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050169908A1 (en) * | 2004-01-23 | 2005-08-04 | Kazunori Murakami | Use of aerosolized antithrombin to treat acute lung injury |
| US20050192226A1 (en) * | 2004-02-20 | 2005-09-01 | Perenlei Enkhbaatar | Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants |
| US20050245444A1 (en) * | 2004-04-30 | 2005-11-03 | Yann Echelard | Method of using recombinant human antithrombin for neurocognitive disorders |
| US20060121004A1 (en) * | 2004-12-07 | 2006-06-08 | Yann Echelard | Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin |
| WO2012051339A2 (en) * | 2010-10-12 | 2012-04-19 | Vetgel Technologies | Methods and compositions for treating respiratory conditions using platelet enriched plasma |
| WO2012090067A1 (en) | 2010-12-30 | 2012-07-05 | Lfb Biotechnologies | Glycols as pathogen inactivating agents |
| US10174110B2 (en) | 2013-02-13 | 2019-01-08 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Highly galactosylated anti-TNF-α antibodies and uses thereof |
| WO2014140927A2 (en) | 2013-02-13 | 2014-09-18 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| KR20160029840A (ko) | 2013-07-05 | 2016-03-15 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | 친화성 크로마토그래피 매트릭스 |
| JP6779866B2 (ja) | 2014-06-13 | 2020-11-04 | チルドレンズ メディカル センター コーポレイション | ミトコンドリアを単離するための製品および方法 |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| WO2017124037A1 (en) | 2016-01-15 | 2017-07-20 | The Children's Medical Center Corporation | Therapeutic use of mitochondria and combined mitochondrial agents |
| WO2020214644A1 (en) * | 2019-04-15 | 2020-10-22 | Children's Medical Center Corporation | Aerosolized compositions comprising mitochondria and methods of use thereof |
| JP2024509735A (ja) * | 2021-02-17 | 2024-03-05 | ユニヴァーシティ オヴ ロチェスター | 敗血症の予後を処置、診断及び予測する方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08782B2 (ja) * | 1986-11-22 | 1996-01-10 | 株式会社ミドリ十字 | 抗炎症剤 |
| DE4117078A1 (de) * | 1991-05-25 | 1992-11-26 | Boehringer Ingelheim Kg | Verfahren zur herstellung therapeutisch anwendbarer aerosole |
| JPH06256213A (ja) * | 1993-03-03 | 1994-09-13 | Green Cross Corp:The | ヒト由来アンチトロンビン−ｉｉｉの医薬用途 |
| US6127347A (en) * | 1994-01-12 | 2000-10-03 | Univ Michigan | Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes |
| US6355626B1 (en) * | 1994-05-13 | 2002-03-12 | The Trustees Of The University Of Pennsylvania | Antithrombin agents in treatment of asthma |
| US5843705A (en) * | 1995-02-21 | 1998-12-01 | Genzyme Transgenic Corporation | Transgenically produced antithrombin III |
| US6562781B1 (en) * | 1995-11-30 | 2003-05-13 | Hamilton Civic Hospitals Research Development Inc. | Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
| US7045585B2 (en) * | 1995-11-30 | 2006-05-16 | Hamilton Civic Hospital Research Development Inc. | Methods of coating a device using anti-thrombin heparin |
| JPH09176040A (ja) * | 1995-12-27 | 1997-07-08 | Green Cross Corp:The | ヘパリンコファクターｉｉの医薬用途 |
| US6063593A (en) * | 1996-11-12 | 2000-05-16 | University Of Southern California University Park Campus | TGFβ1 responsive bone marrow derived cells to express a recombinant protein |
| US6124257A (en) * | 1997-08-28 | 2000-09-26 | Lezdey; John | Method of treatment |
| IL142639A0 (en) * | 1998-10-20 | 2002-03-10 | Childrens Hosp Medical Center | Surfactant protein d for the prevention and diagnosis of pulmonary emphysema |
| US6838428B2 (en) * | 1998-10-20 | 2005-01-04 | Children's Hospital Medical Center | Surfactant protein D for the prevention and diagnosis of pulmonary emphysema |
| DE10045047A1 (de) * | 2000-09-12 | 2002-03-21 | Beate Kehrel | Arzneimittel enthaltend aktiviertes Antithrombin III |
| AU2002224408B2 (en) * | 2000-10-18 | 2007-08-23 | Massachusetts Institute Of Technology | Methods and products related to pulmonary delivery of polysaccharides |
| DE10132307A1 (de) * | 2001-07-06 | 2003-01-30 | Aventis Behring Gmbh | Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS |
| US20050169908A1 (en) * | 2004-01-23 | 2005-08-04 | Kazunori Murakami | Use of aerosolized antithrombin to treat acute lung injury |
| US20050192226A1 (en) * | 2004-02-20 | 2005-09-01 | Perenlei Enkhbaatar | Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants |
-
2003
- 2003-03-25 AU AU2003233428A patent/AU2003233428B2/en not_active Revoked
- 2003-03-25 EP EP03728277A patent/EP1494696A4/en not_active Withdrawn
- 2003-03-25 IL IL16407803A patent/IL164078A0/xx active IP Right Grant
- 2003-03-25 CN CNB03807463XA patent/CN100384469C/zh not_active Expired - Fee Related
- 2003-03-25 WO PCT/US2003/009053 patent/WO2003084476A2/en not_active Ceased
- 2003-03-25 KR KR10-2004-7015636A patent/KR20040105838A/ko not_active Ceased
- 2003-03-25 KR KR1020107022448A patent/KR20100117148A/ko not_active Ceased
- 2003-03-25 US US10/396,855 patent/US20090221475A9/en not_active Abandoned
- 2003-03-25 CA CA002480790A patent/CA2480790A1/en not_active Abandoned
- 2003-03-25 JP JP2003581716A patent/JP2005527570A/ja active Pending
- 2003-03-25 NZ NZ535487A patent/NZ535487A/en not_active IP Right Cessation
-
2004
- 2004-09-14 IL IL164078A patent/IL164078A/en not_active IP Right Cessation
-
2008
- 2008-10-31 AU AU2008243077A patent/AU2008243077A1/en not_active Withdrawn
-
2011
- 2011-08-12 JP JP2011176604A patent/JP2011225625A/ja not_active Withdrawn
- 2011-10-10 AU AU2011236070A patent/AU2011236070A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003084476A2 (en) | 2003-10-16 |
| IL164078A0 (en) | 2005-12-18 |
| CN1774258A (zh) | 2006-05-17 |
| IL164078A (en) | 2011-02-28 |
| KR20040105838A (ko) | 2004-12-16 |
| US20040192595A1 (en) | 2004-09-30 |
| AU2011236070A1 (en) | 2011-11-03 |
| EP1494696A2 (en) | 2005-01-12 |
| CN100384469C (zh) | 2008-04-30 |
| US20090221475A9 (en) | 2009-09-03 |
| JP2005527570A (ja) | 2005-09-15 |
| AU2003233428A1 (en) | 2003-10-20 |
| CA2480790A1 (en) | 2003-10-16 |
| KR20100117148A (ko) | 2010-11-02 |
| EP1494696A4 (en) | 2006-01-25 |
| WO2003084476A3 (en) | 2004-04-22 |
| JP2011225625A (ja) | 2011-11-10 |
| AU2008243077A1 (en) | 2008-11-27 |
| AU2003233428B2 (en) | 2008-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011236070A1 (en) | Treatment of lung disorder | |
| TWI417108B (zh) | 於肺內區中以半氟化烷類作為活性物質載體的吸入式及滴入式使用 | |
| RU2433841C2 (ru) | Доставка в легкие альфа-1-ингибитора протеиназ | |
| EP0502054B1 (en) | An aerosol preparation of glutathione and a method for augmenting glutathione level in lungs | |
| JPH03501852A (ja) | エアゾール化したポリエンを用いる肺の真菌感染の予防及び治療方法 | |
| ZA200600773B (en) | Inhalable formulations for treating pulmonary hypertension and methods of using same | |
| US5723439A (en) | Pharmaceutical aerosol composition and application thereof for treatment and prophylaxis of viral diseases | |
| US20200268656A1 (en) | Nebulized Ethanol for Internal Disinfecting and Improvement | |
| JP2015232026A (ja) | 人工呼吸器関連肺炎（ｖａｐ）及び人工呼吸器関連気管（ｖａｔ）気管支炎の治療のためのアミカシンとホスホマイシンの組み合わせの製剤並びに方法及びシステム | |
| EP4232073B1 (en) | New dosage regimen for inhaled vasoactive intestinal polypeptide | |
| EP1725244B1 (en) | Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants | |
| KR101924162B1 (ko) | 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손 | |
| RU2737799C1 (ru) | Ингаляционный гексапептид для лечения респираторных заболеваний, связанных с интерлейкином-6 | |
| HK1087930A (en) | Treatment of lung disorder | |
| KR20100093037A (ko) | 폐질환의 건강 관련 삶의 질 부족을 치료하기 위한 흡입용 아즈트레오남 라이신 | |
| TW201016215A (en) | Compositions and uses of antiviral active pharmaceutical agents | |
| CN116437903A (zh) | 肝素组合物在通过吸入途径通过软雾吸入器或振动网状技术雾化器治疗病毒性肺病、急性和/或慢性肺病中的用途 | |
| Hashimoto et al. | Aerosolization of imipenem/cilastatin prevents pseudomonas-induced acute lung injury | |
| JP2003513048A (ja) | 気道狭窄の治療のための酸化窒素の使用 | |
| Ibrahim et al. | Inhaled Therapy for Other Respiratory Diseases: Cystic Fibrosis and Non-cystic Fibrosis Bronchiectasis | |
| RS66259B1 (sr) | Primena dalargina za prevenciju virusnih respiratornih infekcija i prevenciju razvoja komplikacija tokom virusnih respiratornih infekcija | |
| Challoner | Aerosol delivery of antibiotics | |
| US20040157772A1 (en) | Use of a gatran for the manufacture of a medicament of the treatment of pulmonary fibrosis | |
| KR20230008844A (ko) | Covid-19의 예방 또는 치료를 위한 펩티드 | |
| Bauer et al. | Special Applications of Aerosol Therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CORR | Corrigendum |
Free format text: ADVERTISED IN JOURNAL 1553 AS "VOID" IN ERROR. THE STATUS OF THE APPLICATION IS PENDING/UNDER EXAMINATION |
|
| S883 | Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant) |
Free format text: THE APPLICANT (71) HAS BEEN CORRECTED |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| S883 | Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant) |
Free format text: CORRECTION TO PATENTEE (71) |
|
| LAPS | Patent lapsed |